Innovation through proprietary technology platforms

Our Activities

Innovation for the future

Product Pipeline

Our entry to the world


Operational excellence


Our new manufacturing site in Madrid


Direct presence in Spain & Portugal


Our Activities

“Our activities are defined by constant research and development. We innovate with a focus on our proprietary technology platforms. Our own EU and FDA approved manufacturing facilities in Spain and the US make us flexible and efficient”

Alberto Bueno, CEO


Our strength

Innovation is the fuel that drives our business. Whether through projects stemming from the company’s in-house R&D or by partnering with public and private research groups, our research is focused around three therapeutic areas: Otolaryngology, Ophthalmology and Gastroenterology. All products developed by Salvat share a common goal, to provide innovative solutions to improve people’s quality of life.

Additionally, we offer our R&D services to other companies interested in the potential of our proprietary technologies and the skills of our internal development team. We offer contract development services for products inside and outside our core therapeutic areas.

Gastroenterology has been one of Salvat’s areas of focus since our foundation. Our Orally Dispersible Tablets (ODT) are an innovative technology that has been licensed-out worldwide. Salvat’s Multiparticulate platform is a technology platform with the capability of providing a drug delivery toolbox with “on demand” oral drug release profiles through the digestive tract. The result of our R&D in Gastroenterology is present in Monolitum® Flas, the leading lansoprazole brand in Spain. We also have Levogastrol for dysmotility-like functional dyspepsia and Nutira, an innovative line of products for Lactose intolerance.

Salvat is a world leader in otolaryngology. Our constant innovation in the field has allowed us to lead the Spanish market and to achieve constant growth in other geographies.
Cetraxal ®, Otovel®, Tinnitan® and Saletego® are a few of the many specialty brands we’ve built with an exclusive focus on otolaryngology.

Taking advantage of our existing technology platforms, in 2010 we ventured into ophthalmology. We use Blow-Fill-Seal technology for the development of sterile, preservative free ophthalmic solutions that improve convenience and compliance.
Our ophthalmic products include Tebarat®, Cetraflux®, Ursitan® and the umbrella brand Relive®, that includes food supplements, medical devices and drugs for the treatment of dry eye.

New Therapeutic Entities

Product Pipeline

Innovation for the future

We focus our research on three therapeutic areas: otolaryngology, ophthalmology and gastroenterology, but also with an eye on the local OTC market. Our proprietary technology platforms are the core of our innovation. This allows us to develop new formulations and new combinations, which target novel indications with already-known molecules. These are our new therapeutic entities. Our goal is to develop products that improve convenience and compliance, therefore improving the quality of life of our patients.


Development of a product in single-dose containers, preservative-free, for the treatment of fungal otitis externa (otomycosis). Two twin phase III clinical trials have been completed in the USA, Mexico, and Europe, which have demonstrated the efficacy and safety of the product. These studies are the basis for worldwide marketing approval, which would constitute the first FDA-approved drug for the treatment of otomycosis.


Topical corticosteroid of medium potency, formulated for the treatment of otic eczema. It is presented in single-dose containers, which makes its administration very convenient for the intended indication.


New moisturizing nasal product, combining well-known efficacious components in a smart polymer formulation, for the relief of dry, irritated nose caused by various conditions, including common cold, sinusitis, allergies, and others. The product will be formulated as a spray, so the ease of use will be a differentiating characteristic compared to most competitors.


New therapeutic entity for the treatment of inflammation and pain that occur after ocular surgery. It is an innovative product since the active ingredient has never been used before in ophthalmology, in single-dose format, and most importantly, formulated with IMPACT-SVT®, a patented nanoemulsion drug delivery technology, which facilitates its therapeutic effect and the tolerability of the product.


Development of an NSAID in single-dose containers, preservative-free, for the treatment of inflammation and pain after ocular surgery. Importantly, the product has never been formulated as a single dose before, so this new project will bring a more convenient administration for the patients.


Development of a combination of prostaglandin analogue and beta-blocker for the treatment of glaucoma. It is being developed in single-dose containers, preservative-free, allowing for a very convenient administration.


Development of a combination of prostaglandin analogue and beta-blocker for the treatment of glaucoma. It is being developed in single-dose containers, allowing for a very convenient administration.


New therapeutic entity with a novel combination of an antibiotic and a corticosteroid for the topical treatment of ocular infections. It will be formulated in single-dose containers. Pre-clinical studies have been performed, and the clinical development phases are expected to be initiated shortly.


New therapeutic entity for the treatment of episodic dry eye disease. It will be formulated in single-dose containers, as a nanoemulsion, using a patented drug delivery technology (IMPACT-SVT®) and allowing for a precise administration with enhanced penetration and high tolerability.


New developmental product for the treatment of moderate to severe chronic dry eye disease. In preliminary animal studies, the results have been very promising, and the clinical phases of the development are expected to be initiated in a short time.


Development of a topical corticosteroid for the treatment of Diabetic Macular Edema, which will be formulated as a topical ophthalmic nanoemulsion in single-dose containers, by using Salvat’s patented technology (IMPACT-SVT®) and allowing for an enhanced penetration for reaching the affected retina.


New therapeutic entity for the treatment of Diabetic Retinopathy. It will be formulated as topical eye drops, in single-dose containers by using Salvat’s patented technology (IMPACT-SVT®) to enhance penetration and reach the patient’s retina.

Bonecure (SVT-1001)

Bonecure is a cell therapy project, in which allogeneic mesenchymal stem cells subjected to a specific pre-differentiation process are used, for the treatment of patients with post-fracture bone consolidation problems. The cells are applied locally by implanting calcium phosphate supports into which the cells have previously been inoculated.


Together we are stronger

Salvat’s sustainability depends on our ability to develop truly innovative products targeting important unmet needs. Our constant growth wouldn’t be possible without a large network of top-tier international partners. They assist us in identifying market needs and they know the key to success in every region.

Salvat also has fully integrated CDMO services, to ensure your project’s commercial success. We offer the latest technologies with optimum quality, flexibility, and operational excellence.

With over 69 years of experience, we can provide the services and solutions that make our partners successful.

For more information visit the section “Partnering and Services


Operational excellence

We own three spanish manufacturing sites located in Esplugues de Llobregat (Barcelona) and Alcalá de Henares (Madrid), this one is FDA approved. Our Blow-Fill-Seal line of sterile liquids, in partnership with Aveva, is located in Tamarac, Florida and is FDA approved. Each of our sites is equipped with the latest technology and complies with GMP regulations.


Our new manufacturing site in Madrid

With the acquisition of Pharmaloop, Salvat expands its capacity in the manufacturing of solid and liquid products, and establishes the foundation for further expansion in sterile manufacturing.

Visit Pharmaloop website


Direct presence in Spain and Portugal

Since our foundation in 1955, we have commercialized our products in Spain through our own marketing & sales structure. Our direct presence has helped us build a strong reputation amongst doctors and pharmacists who continue to prescribe our brands nationwide.

Our sales and marketing team exceeds 100 professionals, all of them with vast market expertise.